Latest On Agios Pharmaceuticals, Inc (AGIO):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-24 13:19 EST | News | Agios Pharmaceuticals: Good Execution, A Good Deal Of Cash, Some Hurdles | N/A |  |
| 2023-05-04 22:01 EST | News | Agios Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2023-05-04 22:01 EST | News | Agios Pharmaceuticals, Inc. (AGIO) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-04 09:00 EST | News | Agios Pharmaceuticals GAAP EPS of -$1.47 beats by $0.23, revenue of $5.6M beats by $0.37M | N/A | |
| 2023-05-03 20:46 EST | News | Agios Pharmaceuticals Q1 2023 Earnings Preview | N/A | |
| 2023-02-24 01:00 EST | News | Agios Pharmaceuticals, Inc. (AGIO) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-02-23 11:31 EST | News | Agios Pharmaceuticals GAAP EPS of -$4.23 beats by $2.06, revenue of $14.24M beats by $0.35M | N/A | |
| 2023-02-22 09:46 EST | News | Agios Pharma: Multiple Growth Catalysts If Pyrukynd Conversions Pull Through | N/A | |
| 2023-01-11 19:46 EST | News | Agios Pharmaceuticals (AGIO) presents at 41st Annual J.P. Morgan Healthcare Conference - Slideshow | N/A | |
| 2022-12-12 09:07 EST | News | Agios rare blood disorder drug Pyrukynd sustains benefits in patients in long term data | N/A | |
| 2022-11-17 17:06 EST | News | Agios Pharmaceuticals upgraded to neutral at Goldman Sachs on Pyrukynd outlook | N/A | |
| 2022-11-12 00:39 EST | News | Agios granted EU approval for Pyrukynd in pyruvate kinase deficiency | N/A | |
| 2022-11-04 15:26 EST | News | Agios Pharmaceuticals, Inc. (AGIO) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-04 15:26 EST | News | Agios Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation | N/A | |
| 2022-11-03 22:53 EST | News | Agios Pharmaceuticals GAAP EPS of -$1.49 beats by $0.27, revenue of $3.52M misses by $1.72M | N/A | |
| 2022-10-30 23:18 EST | News | Agios Pharmaceuticals: A Big Year On The Horizon | N/A | |
| 2022-10-27 21:23 EST | News | Agios sells its rights to royalties on U.S. sales of cancer drug Tibsovo for $131.8M | N/A | |
| 2022-09-19 18:38 EST | News | Agios appoints Cecilia Jones as finance chief | N/A | |
| 2022-09-16 22:56 EST | News | Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU | N/A | |
| 2022-09-07 13:53 EST | News | Agios CFO Jonathan Biller to quit | N/A | |
| 2022-09-01 18:52 EST | News | Agios adds more than 13% after Novo deal to acquire rival Forma | N/A | |
| 2022-08-07 19:20 EST | News | Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-07 19:20 EST | News | Agios Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-08-04 23:04 EST | News | Agios stock rises as Q2 sees new drug Pyrukynd bring in revenue | N/A | |
| 2022-08-04 07:32 EST | News | Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07 | N/A | |
| 2022-07-27 15:35 EST | News | Agios gains as blood disorder therapy draws positive views | N/A | |
| 2022-07-26 12:48 EST | News | Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp | N/A | |
| 2022-07-12 22:36 EST | News | Agios Pharmaceuticals hires new CEO | N/A | |
| 2022-07-12 22:36 EST | News | Agios Pharmaceuticals appoints new board chair, CEO | N/A | |
| 2022-06-18 02:50 EST | News | Agios Pharmaceuticals (AGIO) Presents At EHA 2022 Conference - Slideshow | N/A | |
| 2022-05-18 02:34 EST | News | Agios chief scientific officer to depart amid layoffs as company pivots to genetic diseases | N/A | |
| 2022-05-10 23:23 EST | News | Agios: Approved Product, Upcoming Catalysts | N/A | |
| 2022-05-10 01:38 EST | News | Agios Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation | N/A | |
| 2022-05-05 20:57 EST | News | Agios Pharmaceuticals GAAP EPS of -$1.74 beats by $0.07, revenue of $0.83M misses by $1.88M | N/A | |
| 2022-05-05 20:57 EST | News | Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-04 22:11 EST | News | Agios Pharmaceuticals Q1 2022 Earnings Preview | N/A | |
| 2022-02-25 04:07 EST | News | Agios Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-02-25 04:06 EST | News | Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-24 08:21 EST | News | Agios Pharmaceuticals Q4 2021 Earnings Preview | N/A | |
| 2022-02-24 08:20 EST | News | Agios Pharmaceuticals GAAP EPS of -$1.81 misses by $0.12 | N/A | |
| 2022-02-23 12:21 EST | News | Agios Pharmaceuticals With FDA Approval Is A Buy | N/A | |
| 2022-02-19 06:37 EST | News | Agios Pharmaceuticals' mitapivat approved by FDA for pyruvate kinase deficiency | N/A | |
| 2022-02-19 06:36 EST | News | Agios vindicated with FDA approval for Pyrukynd - H.C. Wainwright | N/A | |
| 2022-02-18 08:40 EST | News | Agios Pyrukynd for rare blood disorder gets US FDA approval | N/A | |
| 2022-01-20 15:39 EST | News | Agios Before The February PDUFA | N/A | |
| 2021-12-14 09:40 EST | News | Agios presents mitapivat long-term data in PK deficiency at ASH 2021 | N/A | |
| 2021-11-04 03:28 EST | News | Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-04 03:28 EST | News | Agios Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation | N/A | |
| 2021-11-03 07:29 EST | News | Agios Pharmaceuticals EPS beats by $1.46 | N/A | |
| 2021-11-02 11:38 EST | News | Agios Pharmaceuticals Q3 2021 Earnings Preview | N/A | |
About Agios Pharmaceuticals, Inc (AGIO):
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
General
- Name Agios Pharmaceuticals, Inc
- Symbol AGIO
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 562
- Fiscal Year EndDecember
- IPO Date2013-07-24
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.agios.com
View More
Valuation
- Forward PE 8.1
- Price/Sales (Trailing 12 Mt.) 17.51
- Price/Book (Most Recent Quarter) 8.98
- Enterprise Value Revenue 15.36
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$6.07
- Next Year EPS Estimate -$6.10
- Next Quarter EPS Estimate -$1.29
- Profit Margin -161%
- Operating Margin -156%
- Return on Assets -23%
- Return on Equity -63%
- Revenue 203.2 million
- Earnings Per Share -$6.67
- Revenue Per Share $2.95
- Gross Profit -167079000
- Quarterly Earnings Growth 24.3%
View More
Highlights
- Market Capitalization 3.38 billion
- EBITDA -399112000
- PE Ratio 1.11
- Analyst Target Price $64.89
- Book Value Per Share $5.77
View More
Share Statistics
- Shares Outstanding 69.36 million
- Shares Float 61.75 million
- % Held by Insiders 1133%
- % Held by Institutions 92.34%
- Shares Short 5.82 million
- Shares Short Prior Month 5.68 million
- Short Ratio 8.4
- Short % of Float 11%
- Short % of Shares Outstanding 8%
View More
Technicals
- Beta 1.62
- 52 Week High $58.93
- 52 Week Low $32.47
- 50 Day Moving Average 50.87
- 200 Day Moving Average 42.95
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Agios Pharmaceuticals, Inc (AGIO) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Agios Pharmaceuticals, Inc (AGIO) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-25 | $44.05 million | -$1.41 | -$1.31 | -7.96% |
| 2020-09-30 | 2020-11-05 | $34.71 million | -$1.43 | -$1.36 | -5.47% |
| 2020-06-30 | 2020-07-30 | $N/A | -$1.31 | -$1.36 | 3.72% |
| 2020-03-31 | 2020-04-30 | $N/A | -$0.59 | -$1.64 | 63.94% |
| 2019-12-31 | 2020-02-13 | $35.44 million | -$1.60 | -$1.68 | 4.94% |
| 2019-09-30 | 2019-10-31 | $26.02 million | -$1.81 | -$1.81 | -0.22% |
| 2019-06-30 | 2019-08-01 | $26.22 million | -$1.87 | -$1.70 | -9.89% |
| 2019-03-31 | 2019-05-02 | $30.23 million | -$1.59 | -$1.75 | 9.24% |
| 2018-12-31 | 2019-02-14 | $30.01 million | -$1.58 | -$1.66 | 4.62% |
| 2018-09-30 | 2018-11-01 | $15.2 million | -$1.63 | -$1.62 | -0.73% |
| 2018-06-30 | 2018-08-02 | $40.41 million | -$1.19 | -$1.55 | 23.07% |
| 2018-03-31 | 2018-05-04 | $8.76 million | -$1.63 | -$1.65 | 1.41% |
| 2017-12-31 | 2018-02-14 | $9.8 million | -$1.81 | -$1.61 | -12.63% |
| 2017-09-30 | 2017-11-01 | $11.36 million | -$1.59 | -$1.78 | 10.46% |
| 2017-06-30 | 2017-08-08 | $11.35 million | -$1.78 | -$1.57 | -13.53% |
| 2017-03-31 | 2017-05-04 | $10.51 million | -$1.56 | -$1.80 | 13.19% |
| 2016-12-31 | 2017-02-16 | $22.65 million | -$1.34 | -$1.51 | 11.38% |
| 2016-09-30 | 2016-11-03 | $8.99 million | -$1.63 | -$1.51 | -8.2% |
| 2016-06-30 | 2016-08-04 | $6.98 million | -$1.47 | -$1.30 | -12.77% |
| 2016-03-31 | 2016-05-05 | $31.28 million | -$0.61 | -$0.93 | 34.47% |
| 2015-12-31 | 2016-02-18 | $6.22 million | -$1.08 | -$0.53 | -102.21% |
| 2015-09-30 | 2015-11-05 | $5.48 million | -$1.07 | -$0.88 | -21.59% |
| 2015-06-30 | 2015-08-06 | $13.22 million | -$0.85 | -$0.46 | -84.78% |
| 2015-03-31 | 2015-05-07 | $34.2 million | -$0.13 | -$0.92 | 85.87% |
| 2014-12-31 | 2015-02-17 | $14.64 million | -$0.76 | -$0.58 | -31.03% |
| 2014-09-30 | 2014-11-07 | $33.9 million | $0.10 | -$0.52 | 119.23% |
| 2014-06-30 | 2014-08-07 | $8.41 million | -$0.54 | -$0.40 | -35% |
| 2014-03-31 | 2014-05-08 | $8.41 million | -$0.39 | -$0.37 | -5.41% |
| 2013-12-31 | 2014-03-06 | $6.74 million | -$0.40 | -$0.34 | -17.65% |
| 2013-09-30 | 2013-11-07 | $6.27 million | -$0.47 | -$0.29 | -62.07% |
| 2013-06-30 | 2013-09-05 | $6.27 million | -$2.80 | -$0.32 | -775% |
Agios Pharmaceuticals, Inc (AGIO) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Agios Pharmaceuticals, Inc (AGIO) Chart:
Agios Pharmaceuticals, Inc (AGIO) News:
Below you will find a list of latest news for Agios Pharmaceuticals, Inc (AGIO) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Agios Pharmaceuticals, Inc (AGIO) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 12.5 | 0 | CALL | 0 | 0 | 348.36 | TRUE | 0 | 0 |
| 2024-05-17 | 15 | 0 | CALL | 0 | 0 | 243.9 | TRUE | 0 | 0 |
| 2024-05-17 | 17.5 | 0 | CALL | 0 | 0 | 232.04 | TRUE | 0 | 0 |
| 2024-05-17 | 20 | 4.2 | CALL | 0 | 5 | 194.05 | TRUE | 0 | 0 |
| 2024-05-17 | 22.5 | 3.6 | CALL | 0 | 15 | 159.58 | TRUE | 0 | 0 |
| 2024-05-17 | 25 | 5.99 | CALL | 0 | 1509 | 111.33 | TRUE | 0 | 0 |
| 2024-05-17 | 30 | 2.5 | CALL | 5 | 96 | 49.33 | TRUE | 0.05 | 0.02 |
| 2024-05-17 | 35 | 0.75 | CALL | 0 | 387 | 51.21 | FALSE | 0 | 0 |
| 2024-05-17 | 40 | 0.3 | CALL | 0 | 133 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 45 | 0.15 | CALL | 0 | 40 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 50 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 12.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 15 | 0.35 | PUT | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 17.5 | 0.23 | PUT | 0 | 4 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 20 | 0.1 | PUT | 0 | 55 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 22.5 | 0.15 | PUT | 0 | 3 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 25 | 0.1 | PUT | 0 | 18 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 30 | 0.8 | PUT | 1 | 131 | 51.56 | FALSE | 0.8 | 0 |
| 2024-05-17 | 35 | 0 | PUT | 0 | 0 | 58.81 | TRUE | 0 | 0 |
| 2024-05-17 | 40 | 0 | PUT | 0 | 0 | 87.44 | TRUE | 0 | 0 |
| 2024-05-17 | 45 | 0 | PUT | 0 | 0 | 132.56 | TRUE | 0 | 0 |
| 2024-05-17 | 50 | 0 | PUT | 0 | 0 | 165.61 | TRUE | 0 | 0 |
| 2024-06-21 | 12.5 | 0 | CALL | 0 | 0 | 195.92 | TRUE | 0 | 0 |
| 2024-06-21 | 15 | 0 | CALL | 0 | 0 | 155.07 | TRUE | 0 | 0 |
| 2024-06-21 | 17.5 | 0 | CALL | 0 | 0 | 107.4 | TRUE | 0 | 0 |
| 2024-06-21 | 20 | 4.29 | CALL | 0 | 5 | 105.78 | TRUE | 0 | 0 |
| 2024-06-21 | 22.5 | 6.4 | CALL | 0 | 326 | 96.17 | TRUE | 0 | 0 |
| 2024-06-21 | 25 | 6.44 | CALL | 0 | 305 | 78.04 | TRUE | 0 | 0 |
| 2024-06-21 | 30 | 3.92 | CALL | 0 | 356 | 56.53 | TRUE | 0 | 0 |
| 2024-06-21 | 35 | 1.09 | CALL | 0 | 70 | 41.78 | FALSE | 0 | 0 |
| 2024-06-21 | 40 | 0.3 | CALL | 0 | 23 | 42.96 | FALSE | 0 | 0 |
| 2024-06-21 | 45 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 50 | 0.35 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 12.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 15 | 0.11 | PUT | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 17.5 | 0.18 | PUT | 0 | 39 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 20 | 0.1 | PUT | 0 | 315 | 99.92 | FALSE | 0 | 0 |
| 2024-06-21 | 22.5 | 0.67 | PUT | 0 | 49 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 25 | 0.9 | PUT | 0 | 1346 | 52.25 | FALSE | 0 | 0 |
| 2024-06-21 | 30 | 2.79 | PUT | 0 | 300 | 47.39 | FALSE | 0 | 0 |
| 2024-06-21 | 35 | 6.4 | PUT | 0 | 1001 | 49.34 | TRUE | 0 | 0 |
| 2024-06-21 | 40 | 0 | PUT | 0 | 0 | 66.16 | TRUE | 0 | 0 |
| 2024-06-21 | 45 | 0 | PUT | 0 | 0 | 73.51 | TRUE | 0 | 0 |
| 2024-06-21 | 50 | 0 | PUT | 0 | 0 | 86.41 | TRUE | 0 | 0 |
| 2024-08-16 | 12.5 | 0 | CALL | 0 | 0 | 144.63 | TRUE | 0 | 0 |
| 2024-08-16 | 15 | 0 | CALL | 0 | 0 | 118.75 | TRUE | 0 | 0 |
| 2024-08-16 | 17.5 | 0 | CALL | 0 | 0 | 95.34 | TRUE | 0 | 0 |
| 2024-08-16 | 20 | 0 | CALL | 0 | 0 | 73.57 | TRUE | 0 | 0 |
| 2024-08-16 | 22.5 | 12 | CALL | 0 | 278 | 69.59 | TRUE | 0 | 0 |
| 2024-08-16 | 25 | 7.5 | CALL | 0 | 277 | 35.93 | TRUE | 0 | 0 |
| 2024-08-16 | 30 | 2.97 | CALL | 0 | 65 | 44.42 | TRUE | 0 | 0 |
| 2024-08-16 | 35 | 1.6 | CALL | 0 | 300 | 37.52 | FALSE | 0 | 0 |
| 2024-08-16 | 40 | 2.7 | CALL | 0 | 1 | 38.93 | FALSE | 0 | 0 |
| 2024-08-16 | 45 | 0.5 | CALL | 0 | 30 | 41.41 | FALSE | 0 | 0 |
| 2024-08-16 | 50 | 0.8 | CALL | 0 | 5 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 12.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 15 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 17.5 | 1 | PUT | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 20 | 0.26 | PUT | 0 | 50 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 22.5 | 2 | PUT | 0 | 275 | 46.22 | FALSE | 0 | 0 |
| 2024-08-16 | 25 | 4.64 | PUT | 0 | 275 | 45.22 | FALSE | 0 | 0 |
| 2024-08-16 | 30 | 3.09 | PUT | 0 | 100 | 42.25 | FALSE | 0 | 0 |
| 2024-08-16 | 35 | 0 | PUT | 0 | 0 | 34.73 | TRUE | 0 | 0 |
| 2024-08-16 | 40 | 0 | PUT | 0 | 0 | 38.98 | TRUE | 0 | 0 |
| 2024-08-16 | 45 | 0 | PUT | 0 | 0 | 57.43 | TRUE | 0 | 0 |
| 2024-08-16 | 50 | 0 | PUT | 0 | 0 | 75.03 | TRUE | 0 | 0 |
| 2024-11-15 | 17.5 | 0 | CALL | 0 | 0 | 78.27 | TRUE | 0 | 0 |
| 2024-11-15 | 20 | 0 | CALL | 0 | 0 | 68.96 | TRUE | 0 | 0 |
| 2024-11-15 | 22.5 | 0 | CALL | 0 | 0 | 57.11 | TRUE | 0 | 0 |
| 2024-11-15 | 25 | 0 | CALL | 0 | 0 | 47.01 | TRUE | 0 | 0 |
| 2024-11-15 | 30 | 0 | CALL | 0 | 0 | 49.01 | TRUE | 0 | 0 |
| 2024-11-15 | 35 | 2.6 | CALL | 0 | 4 | 40.81 | FALSE | 0 | 0 |
| 2024-11-15 | 40 | 1.7 | CALL | 0 | 4 | 39.01 | FALSE | 0 | 0 |
| 2024-11-15 | 45 | 0 | CALL | 0 | 0 | 37.18 | FALSE | 0 | 0 |
| 2024-11-15 | 17.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 20 | 0 | PUT | 0 | 0 | 49.65 | FALSE | 0 | 0 |
| 2024-11-15 | 22.5 | 0 | PUT | 0 | 0 | 41.88 | FALSE | 0 | 0 |
| 2024-11-15 | 25 | 0 | PUT | 0 | 0 | 40.4 | FALSE | 0 | 0 |
| 2024-11-15 | 30 | 0 | PUT | 0 | 0 | 36.76 | FALSE | 0 | 0 |
| 2024-11-15 | 35 | 0 | PUT | 0 | 0 | 35.51 | TRUE | 0 | 0 |
| 2024-11-15 | 40 | 0 | PUT | 0 | 0 | 42.37 | TRUE | 0 | 0 |
| 2024-11-15 | 45 | 0 | PUT | 0 | 0 | 49.25 | TRUE | 0 | 0 |
| 2024-12-20 | 12.5 | 0 | CALL | 0 | 0 | 92.63 | TRUE | 0 | 0 |
| 2024-12-20 | 15 | 0 | CALL | 0 | 0 | 76.03 | TRUE | 0 | 0 |
| 2024-12-20 | 17.5 | 0 | CALL | 0 | 0 | 69.25 | TRUE | 0 | 0 |
| 2024-12-20 | 20 | 4.68 | CALL | 0 | 1 | 67.2 | TRUE | 0 | 0 |
| 2024-12-20 | 22.5 | 3.8 | CALL | 0 | 10 | 41.14 | TRUE | 0 | 0 |
| 2024-12-20 | 25 | 12.7 | CALL | 0 | 7 | 35.36 | TRUE | 0 | 0 |
| 2024-12-20 | 30 | 4.9 | CALL | 0 | 9 | 42.81 | TRUE | 0 | 0 |
| 2024-12-20 | 35 | 5.3 | CALL | 0 | 16 | 39.29 | FALSE | 0 | 0 |
| 2024-12-20 | 40 | 3.2 | CALL | 0 | 27 | 41.9 | FALSE | 0 | 0 |
| 2024-12-20 | 45 | 0 | CALL | 0 | 0 | 38.17 | FALSE | 0 | 0 |
| 2024-12-20 | 50 | 1.8 | CALL | 0 | 5 | 40.67 | FALSE | 0 | 0 |
| 2024-12-20 | 12.5 | 0.15 | PUT | 0 | 9 | 0 | FALSE | 0 | 0 |
| 2024-12-20 | 15 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-12-20 | 17.5 | 0.98 | PUT | 0 | 5 | 0 | FALSE | 0 | 0 |
| 2024-12-20 | 20 | 1.48 | PUT | 0 | 31 | 45.44 | FALSE | 0 | 0 |
| 2024-12-20 | 22.5 | 1.6 | PUT | 0 | 16 | 46.58 | FALSE | 0 | 0 |
| 2024-12-20 | 25 | 4.3 | PUT | 0 | 1 | 46.63 | FALSE | 0 | 0 |
| 2024-12-20 | 30 | 4.8 | PUT | 0 | 327 | 40.69 | FALSE | 0 | 0 |
| 2024-12-20 | 35 | 7.2 | PUT | 0 | 548 | 40.66 | TRUE | 0 | 0 |
| 2024-12-20 | 40 | 0 | PUT | 0 | 0 | 40.13 | TRUE | 0 | 0 |
| 2024-12-20 | 45 | 0 | PUT | 0 | 0 | 46.76 | TRUE | 0 | 0 |
| 2024-12-20 | 50 | 0 | PUT | 0 | 0 | 54.73 | TRUE | 0 | 0 |
| 2025-01-17 | 15 | 0 | CALL | 0 | 0 | 80.93 | TRUE | 0 | 0 |
| 2025-01-17 | 17.5 | 0 | CALL | 0 | 0 | 67.82 | TRUE | 0 | 0 |
| 2025-01-17 | 20 | 0 | CALL | 0 | 0 | 66.18 | TRUE | 0 | 0 |
| 2025-01-17 | 22.5 | 0 | CALL | 0 | 0 | 36.03 | TRUE | 0 | 0 |
| 2025-01-17 | 25 | 7.75 | CALL | 0 | 10 | 42.34 | TRUE | 0 | 0 |
| 2025-01-17 | 30 | 4.72 | CALL | 0 | 37 | 39.33 | TRUE | 0 | 0 |
| 2025-01-17 | 35 | 2.85 | CALL | 0 | 106 | 39.02 | FALSE | 0 | 0 |
| 2025-01-17 | 40 | 2.2 | CALL | 0 | 21 | 37.75 | FALSE | 0 | 0 |
| 2025-01-17 | 45 | 1.17 | CALL | 0 | 15 | 36.81 | FALSE | 0 | 0 |
| 2025-01-17 | 50 | 2 | CALL | 0 | 10 | 39.48 | FALSE | 0 | 0 |
| 2025-01-17 | 15 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 17.5 | 0 | PUT | 0 | 0 | 52.67 | FALSE | 0 | 0 |
| 2025-01-17 | 20 | 0 | PUT | 0 | 0 | 48 | FALSE | 0 | 0 |
| 2025-01-17 | 22.5 | 0 | PUT | 0 | 0 | 46.65 | FALSE | 0 | 0 |
| 2025-01-17 | 25 | 0 | PUT | 0 | 0 | 40.19 | FALSE | 0 | 0 |
| 2025-01-17 | 30 | 0 | PUT | 0 | 0 | 43.5 | FALSE | 0 | 0 |
| 2025-01-17 | 35 | 6.99 | PUT | 0 | 20 | 36.67 | TRUE | 0 | 0 |
| 2025-01-17 | 40 | 0 | PUT | 0 | 0 | 48.37 | TRUE | 0 | 0 |
| 2025-01-17 | 45 | 0 | PUT | 0 | 0 | 41.35 | TRUE | 0 | 0 |
| 2025-01-17 | 50 | 0 | PUT | 0 | 0 | 53.58 | TRUE | 0 | 0 |
Latest AGIO Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 11 | $17.4 |
| Jun 13, 2022 7:59 PM EST | 189 | $17.4 |
| Jun 13, 2022 7:59 PM EST | 128 | $17.4 |
| Jun 13, 2022 7:59 PM EST | 200 | $17.38 |
| Jun 13, 2022 7:59 PM EST | 17 | $17.4 |
Agios Pharmaceuticals, Inc (AGIO) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312520167148/0001193125-20-167148-index.htm |
| 2019-02-04 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000021545719003331/0000215457-19-003331-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000031506619000835/0000315066-19-000835-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000031506620000791/0000315066-20-000791-index.htm |
| 2020-08-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000031506620001684/0000315066-20-001684-index.htm |
| 2019-10-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000083423719000203/0000834237-19-000203-index.htm |
| 2020-02-07 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000083423720008047/0000834237-20-008047-index.htm |
| 2019-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000090221919000091/0000902219-19-000091-index.htm |
| 2020-01-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000090221920000008/0000902219-20-000008-index.htm |
| 2019-01-31 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000093247119002231/0000932471-19-002231-index.htm |
| 2019-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000093247119004832/0000932471-19-004832-index.htm |
| 2019-11-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000110465919064171/0001104659-19-064171-index.htm |
| 2019-11-14 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1439222/000110465919064173/0001104659-19-064173-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000110465920017624/0001104659-20-017624-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000110465920018297/0001104659-20-018297-index.htm |
| 2018-11-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312518314801/0001193125-18-314801-index.htm |
| 2018-11-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312518328948/0001193125-18-328948-index.htm |
| 2018-12-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312518341083/0001193125-18-341083-index.htm |
| 2018-12-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312518353307/0001193125-18-353307-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519003167/0001193125-19-003167-index.htm |
| 2019-01-28 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000119312519018824/0001193125-19-018824-index.htm |
| 2019-02-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519039198/0001193125-19-039198-index.htm |
| 2019-02-14 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1439222/000119312519039513/0001193125-19-039513-index.htm |
| 2019-02-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519051918/0001193125-19-051918-index.htm |
| 2019-04-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519107805/0001193125-19-107805-index.htm |
| 2019-04-18 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1439222/000119312519110870/0001193125-19-110870-index.htm |
| 2019-04-18 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1439222/000119312519110887/0001193125-19-110887-index.htm |
| 2019-05-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519133821/0001193125-19-133821-index.htm |
| 2019-05-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519134882/0001193125-19-134882-index.htm |
| 2019-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519148009/0001193125-19-148009-index.htm |
| 2019-05-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519162771/0001193125-19-162771-index.htm |
| 2019-06-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519164072/0001193125-19-164072-index.htm |
| 2019-06-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519166109/0001193125-19-166109-index.htm |
| 2019-08-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519209747/0001193125-19-209747-index.htm |
| 2019-09-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519237824/0001193125-19-237824-index.htm |
| 2019-09-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519258364/0001193125-19-258364-index.htm |
| 2019-10-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519275491/0001193125-19-275491-index.htm |
| 2019-10-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519279631/0001193125-19-279631-index.htm |
| 2019-11-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519283514/0001193125-19-283514-index.htm |
| 2019-11-06 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1439222/000119312519285887/0001193125-19-285887-index.htm |
| 2019-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519288482/0001193125-19-288482-index.htm |
| 2019-11-08 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1439222/000119312519288495/0001193125-19-288495-index.htm |
| 2019-11-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519298670/0001193125-19-298670-index.htm |
| 2019-12-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312519309199/0001193125-19-309199-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312520005857/0001193125-20-005857-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312520006338/0001193125-20-006338-index.htm |
| 2020-02-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312520034263/0001193125-20-034263-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000119312520037796/0001193125-20-037796-index.htm |
| 2020-02-19 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1439222/000119312520041964/0001193125-20-041964-index.htm |
| 2020-04-16 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1439222/000119312520109284/0001193125-20-109284-index.htm |
| 2020-04-16 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1439222/000119312520109288/0001193125-20-109288-index.htm |
| 2020-04-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312520127627/0001193125-20-127627-index.htm |
| 2020-04-30 | POSASR | Post-effective Amendment to an automatic shelf registration statement | https://www.sec.gov/Archives/edgar/data/1439222/000119312520128793/0001193125-20-128793-index.htm |
| 2020-04-30 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | https://www.sec.gov/Archives/edgar/data/1439222/000119312520128809/0001193125-20-128809-index.htm |
| 2020-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312520155665/0001193125-20-155665-index.htm |
| 2020-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312520155682/0001193125-20-155682-index.htm |
| 2020-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312520167148/0001193125-20-167148-index.htm |
| 2020-07-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312520203351/0001193125-20-203351-index.htm |
| 2020-09-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312520240994/0001193125-20-240994-index.htm |
| 2020-09-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312520249634/0001193125-20-249634-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1439222/000119312520286235/0001193125-20-286235-index.htm |
| 2018-09-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919118050064/0001209191-18-050064-index.htm |
| 2018-09-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919118050631/0001209191-18-050631-index.htm |
| 2018-09-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919118050824/0001209191-18-050824-index.htm |
| 2018-10-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919118054513/0001209191-18-054513-index.htm |
| 2018-11-06 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919118057372/0001209191-18-057372-index.htm |
| 2018-11-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919118057556/0001209191-18-057556-index.htm |
| 2018-11-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919118059146/0001209191-18-059146-index.htm |
| 2018-12-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919118064102/0001209191-18-064102-index.htm |
| 2019-01-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119004950/0001209191-19-004950-index.htm |
| 2019-01-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119004955/0001209191-19-004955-index.htm |
| 2019-01-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119004961/0001209191-19-004961-index.htm |
| 2019-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119007343/0001209191-19-007343-index.htm |
| 2019-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119011483/0001209191-19-011483-index.htm |
| 2019-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119011486/0001209191-19-011486-index.htm |
| 2019-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119011489/0001209191-19-011489-index.htm |
| 2019-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119011491/0001209191-19-011491-index.htm |
| 2019-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119011494/0001209191-19-011494-index.htm |
| 2019-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119011498/0001209191-19-011498-index.htm |
| 2019-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119012942/0001209191-19-012942-index.htm |
| 2019-02-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119013509/0001209191-19-013509-index.htm |
| 2019-02-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119013515/0001209191-19-013515-index.htm |
| 2019-02-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119013525/0001209191-19-013525-index.htm |
| 2019-02-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119013531/0001209191-19-013531-index.htm |
| 2019-02-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119013536/0001209191-19-013536-index.htm |
| 2019-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119014933/0001209191-19-014933-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119016381/0001209191-19-016381-index.htm |
| 2019-03-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119017738/0001209191-19-017738-index.htm |
| 2019-03-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119020288/0001209191-19-020288-index.htm |
| 2019-04-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119023072/0001209191-19-023072-index.htm |
| 2019-04-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119024105/0001209191-19-024105-index.htm |
| 2019-04-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119025785/0001209191-19-025785-index.htm |
| 2019-05-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119033614/0001209191-19-033614-index.htm |
| 2019-05-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119033616/0001209191-19-033616-index.htm |
| 2019-05-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119033618/0001209191-19-033618-index.htm |
| 2019-05-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119033620/0001209191-19-033620-index.htm |
| 2019-05-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119033622/0001209191-19-033622-index.htm |
| 2019-05-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119033625/0001209191-19-033625-index.htm |
| 2019-05-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000120919119033626/0001209191-19-033626-index.htm |
| 2018-11-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1439222/000143922218000018/0001439222-18-000018-index.htm |
| 2019-02-14 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1439222/000143922219000004/0001439222-19-000004-index.htm |
| 2019-05-02 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1439222/000143922219000009/0001439222-19-000009-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922219000011/0001439222-19-000011-index.htm |
| 2019-08-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1439222/000143922219000017/0001439222-19-000017-index.htm |
| 2019-10-31 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1439222/000143922219000021/0001439222-19-000021-index.htm |
| 2019-11-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922219000023/0001439222-19-000023-index.htm |
| 2019-11-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922219000025/0001439222-19-000025-index.htm |
| 2019-12-05 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922219000027/0001439222-19-000027-index.htm |
| 2019-12-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922219000028/0001439222-19-000028-index.htm |
| 2019-12-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922219000030/0001439222-19-000030-index.htm |
| 2020-01-08 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000002/0001439222-20-000002-index.htm |
| 2020-01-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000003/0001439222-20-000003-index.htm |
| 2020-02-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000005/0001439222-20-000005-index.htm |
| 2020-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000006/0001439222-20-000006-index.htm |
| 2020-02-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000008/0001439222-20-000008-index.htm |
| 2020-02-19 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000014/0001439222-20-000014-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000015/0001439222-20-000015-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000016/0001439222-20-000016-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000017/0001439222-20-000017-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000018/0001439222-20-000018-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000019/0001439222-20-000019-index.htm |
| 2020-02-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000020/0001439222-20-000020-index.htm |
| 2020-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000021/0001439222-20-000021-index.htm |
| 2020-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000022/0001439222-20-000022-index.htm |
| 2020-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000023/0001439222-20-000023-index.htm |
| 2020-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000024/0001439222-20-000024-index.htm |
| 2020-02-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000025/0001439222-20-000025-index.htm |
| 2020-02-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000026/0001439222-20-000026-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000027/0001439222-20-000027-index.htm |
| 2020-04-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000028/0001439222-20-000028-index.htm |
| 2020-04-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000029/0001439222-20-000029-index.htm |
| 2020-04-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000030/0001439222-20-000030-index.htm |
| 2020-04-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000031/0001439222-20-000031-index.htm |
| 2020-04-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000032/0001439222-20-000032-index.htm |
| 2020-04-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000033/0001439222-20-000033-index.htm |
| 2020-04-30 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000039/0001439222-20-000039-index.htm |
| 2020-05-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000041/0001439222-20-000041-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000049/0001439222-20-000049-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000050/0001439222-20-000050-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000051/0001439222-20-000051-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000052/0001439222-20-000052-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000053/0001439222-20-000053-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000054/0001439222-20-000054-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000055/0001439222-20-000055-index.htm |
| 2020-07-30 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000059/0001439222-20-000059-index.htm |
| 2020-09-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000061/0001439222-20-000061-index.htm |
| 2020-10-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000063/0001439222-20-000063-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000069/0001439222-20-000069-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000156223019000005/0001562230-19-000005-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1439222/000156223020000005/0001562230-20-000005-index.htm |
| 2019-06-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1439222/000162828019007955/0001628280-19-007955-index.htm |
| 2019-04-26 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1439222/999999999719003422/9999999997-19-003422-index.htm |
| 2019-04-26 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1439222/999999999719003444/9999999997-19-003444-index.htm |
| 2019-07-16 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1439222/999999999719006154/9999999997-19-006154-index.htm |
Agios Pharmaceuticals, Inc (AGIO) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Agios Pharmaceuticals, Inc (AGIO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1133%Institutional Ownership: 9234%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-09-28 | Carman Alenson | Principal Accounting Officer | Sell | 152.00 | 76.45 | 11,620.40 | 0.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119011483/0001209191-19-011483-index.htm |
| 2020-02-16 | David P Schenkein | Director | Buy | 8,125.00 | 105,692.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000015/0001439222-20-000015-index.htm | ||
| 2020-02-22 | David P Schenkein | Director | Buy | 2,775.00 | 105,933.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000022/0001439222-20-000022-index.htm | ||
| 2020-04-13 | Christopher Bowden | Chief Medical Officer | Buy | 5,280.00 | 10,598.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000028/0001439222-20-000028-index.htm | ||
| 2019-03-01 | Steven L. Hoerter | Chief Commercial Officer | Sell | 5,000.00 | 66.01 | 330,050.00 | 10,941.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119016381/0001209191-19-016381-index.htm |
| 2019-03-04 | Steven L. Hoerter | Chief Commercial Officer | Sell | 5,000.00 | 68.00 | 340,000.00 | 10,941.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119016381/0001209191-19-016381-index.htm |
| 2019-04-01 | Christopher Bowden | Chief Medical Officer | Sell | 5,854.00 | 66.03 | 386,539.62 | 11,384.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119023072/0001209191-19-023072-index.htm |
| 2020-05-20 | Christopher Bowden | Chief Medical Officer | Buy | 3,583.00 | 35.16 | 125,978.28 | 11,889.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000041/0001439222-20-000041-index.htm |
| 2019-02-16 | Steven L. Hoerter | Chief Commercial Officer | Buy | 2,750.00 | 11,981.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119011494/0001209191-19-011494-index.htm | ||
| 2019-02-16 | Andrew Hirsch | Chief Financial Officer | Buy | 2,750.00 | 13,195.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119011491/0001209191-19-011491-index.htm | ||
| 2019-05-31 | IAN T CLARK | Director | Buy | 1,400.00 | 1,400.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119033616/0001209191-19-033616-index.htm | ||
| 2019-05-31 | JACQUALYN A FOUSE | Chief Executive Officer | Buy | 1,400.00 | 1,400.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119033620/0001209191-19-033620-index.htm | ||
| 2019-05-31 | Maykin Ho | Director | Buy | 1,400.00 | 1,400.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119033622/0001209191-19-033622-index.htm | ||
| 2019-05-31 | Paul J Clancy | Director | Buy | 1,400.00 | 1,400.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119033614/0001209191-19-033614-index.htm | ||
| 2019-01-20 | Andrew Hirsch | Chief Financial Officer | Buy | 15,000.00 | 15,000.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119004961/0001209191-19-004961-index.htm | ||
| 2019-01-20 | Steven L. Hoerter | Chief Commercial Officer | Buy | 15,000.00 | 15,000.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119004955/0001209191-19-004955-index.htm | ||
| 2020-02-16 | Andrew Hirsch | Chief Financial Officer | Buy | 2,750.00 | 15,127.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000016/0001439222-20-000016-index.htm | ||
| 2020-02-04 | Christopher Bowden | Chief Medical Officer | Buy | 8,526.00 | 35.16 | 299,774.16 | 15,841.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000005/0001439222-20-000005-index.htm |
| 2019-03-01 | Steven L. Hoerter | Chief Commercial Officer | Buy | 5,000.00 | 39.76 | 198,800.00 | 15,941.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119016381/0001209191-19-016381-index.htm |
| 2019-03-04 | Steven L. Hoerter | Chief Commercial Officer | Buy | 5,000.00 | 39.76 | 198,800.00 | 15,941.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119016381/0001209191-19-016381-index.htm |
| 2020-02-04 | Christopher Bowden | Chief Medical Officer | Sell | 14,191.00 | 50.03 | 709,962.96 | 1,650.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000005/0001439222-20-000005-index.htm |
| 2020-02-04 | Christopher Bowden | Chief Medical Officer | Sell | 35,447.00 | 50.10 | 1,776,025.85 | 1,650.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000005/0001439222-20-000005-index.htm |
| 2020-02-11 | Christopher Bowden | Chief Medical Officer | Sell | 621.00 | 50.02 | 31,063.23 | 1,650.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000006/0001439222-20-000006-index.htm |
| 2020-02-13 | Christopher Bowden | Chief Medical Officer | Sell | 7,100.00 | 50.16 | 356,111.86 | 1,650.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000008/0001439222-20-000008-index.htm |
| 2019-03-15 | Christopher Bowden | Chief Medical Officer | Buy | 10,000.00 | 35.16 | 351,600.00 | 17,238.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119020288/0001209191-19-020288-index.htm |
| 2019-04-01 | Christopher Bowden | Chief Medical Officer | Buy | 10,000.00 | 35.16 | 351,600.00 | 17,238.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119023072/0001209191-19-023072-index.htm |
| 2020-02-22 | Andrew Hirsch | Chief Financial Officer | Buy | 3,333.00 | 17,574.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000024/0001439222-20-000024-index.htm | ||
| 2019-11-12 | CORP /DE/ CELGENE | 10% Share Holder | Buy | 403,225.00 | 31.00 | 12,499,975.00 | 1,777,824.00 | https://www.sec.gov/Archives/edgar/data/1439222/000110465919064171/0001104659-19-064171-index.htm |
| 2019-12-26 | Carman Alenson | Principal Accounting Officer | Sell | 2,950.00 | 50.09 | 147,765.50 | 184.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922219000030/0001439222-19-000030-index.htm |
| 2020-02-20 | Carman Alenson | Principal Accounting Officer | Sell | 2,427.00 | 53.37 | 129,528.99 | 184.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000020/0001439222-20-000020-index.htm |
| 2020-02-26 | Carman Alenson | Principal Accounting Officer | Sell | 472.00 | 47.12 | 22,240.64 | 184.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000025/0001439222-20-000025-index.htm |
| 2020-03-02 | Carman Alenson | Principal Accounting Officer | Sell | 345.00 | 47.30 | 16,318.50 | 184.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000027/0001439222-20-000027-index.htm |
| 2020-09-02 | Carman Alenson | Principal Accounting Officer | Sell | 250.00 | 39.93 | 9,982.50 | 184.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000061/0001439222-20-000061-index.htm |
| 2019-05-31 | David Scadden | Director | Buy | 1,400.00 | 1,971.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119033626/0001209191-19-033626-index.htm | ||
| 2020-04-13 | Andrew Hirsch | Chief Financial Officer | Buy | 5,387.00 | 21,905.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000031/0001439222-20-000031-index.htm | ||
| 2018-09-12 | JOHN MARAGANORE | Director | Sell | 14,162.00 | 71.74 | 1,015,981.88 | 22,047.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118050824/0001209191-18-050824-index.htm |
| 2020-02-11 | Christopher Bowden | Chief Medical Officer | Buy | 621.00 | 35.16 | 21,834.36 | 2,271.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000006/0001439222-20-000006-index.htm |
| 2018-12-21 | Scott Biller | Chief Scientific Officer | Buy | 20,500.00 | 2.34 | 47,918.75 | 24,637.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118064102/0001209191-18-064102-index.htm |
| 2020-04-22 | Andrew Hirsch | Chief Financial Officer | Buy | 5,893.00 | 26,199.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000033/0001439222-20-000033-index.htm | ||
| 2019-02-27 | Scott Biller | Chief Scientific Officer | Sell | 9,000.00 | 65.00 | 585,000.00 | 26,511.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119014933/0001209191-19-014933-index.htm |
| 2019-03-05 | Scott Biller | Chief Scientific Officer | Sell | 200.00 | 68.22 | 13,644.00 | 26,511.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119017738/0001209191-19-017738-index.htm |
| 2019-04-05 | Scott Biller | Chief Scientific Officer | Sell | 599.00 | 68.12 | 40,803.88 | 26,511.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119024105/0001209191-19-024105-index.htm |
| 2019-03-05 | Scott Biller | Chief Scientific Officer | Sell | 2,600.00 | 67.73 | 176,098.00 | 26,711.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119017738/0001209191-19-017738-index.htm |
| 2019-03-05 | Scott Biller | Chief Scientific Officer | Buy | 428.00 | 31.64 | 13,541.92 | 26,939.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119017738/0001209191-19-017738-index.htm |
| 2019-04-05 | Scott Biller | Chief Scientific Officer | Sell | 2,401.00 | 67.61 | 162,331.61 | 27,110.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119024105/0001209191-19-024105-index.htm |
| 2019-02-16 | Scott Biller | Chief Scientific Officer | Buy | 2,750.00 | 27,387.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119011486/0001209191-19-011486-index.htm | ||
| 2019-02-27 | Scott Biller | Chief Scientific Officer | Buy | 1,766.00 | 0.47 | 830.02 | 28,277.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119014933/0001209191-19-014933-index.htm |
| 2019-03-05 | Scott Biller | Chief Scientific Officer | Sell | 200.00 | 66.45 | 13,290.00 | 29,311.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119017738/0001209191-19-017738-index.htm |
| 2019-03-05 | Scott Biller | Chief Scientific Officer | Buy | 2,572.00 | 39.76 | 102,262.72 | 29,511.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119017738/0001209191-19-017738-index.htm |
| 2019-04-05 | Scott Biller | Chief Scientific Officer | Buy | 3,000.00 | 39.76 | 119,280.00 | 29,511.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119024105/0001209191-19-024105-index.htm |
| 2020-05-29 | JOHN MARAGANORE | Director | Buy | 1,878.00 | 30,172.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000050/0001439222-20-000050-index.htm | ||
| 2019-02-27 | Scott Biller | Chief Scientific Officer | Buy | 4,154.00 | 9.05 | 37,593.70 | 32,431.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119014933/0001209191-19-014933-index.htm |
| 2020-05-29 | IAN T CLARK | Director | Buy | 1,878.00 | 3,278.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000051/0001439222-20-000051-index.htm | ||
| 2020-05-29 | Maykin Ho | Director | Buy | 1,878.00 | 3,278.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000049/0001439222-20-000049-index.htm | ||
| 2020-05-29 | Paul J Clancy | Director | Buy | 1,878.00 | 3,278.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000053/0001439222-20-000053-index.htm | ||
| 2019-06-11 | Scott Biller | Chief Scientific Officer | Buy | 7,218.00 | 2.34 | 16,872.08 | 33,729.00 | https://www.sec.gov/Archives/edgar/data/1439222/000162828019007955/0001628280-19-007955-index.htm |
| 2019-02-27 | Scott Biller | Chief Scientific Officer | Buy | 3,080.00 | 31.64 | 97,451.20 | 35,511.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119014933/0001209191-19-014933-index.htm |
| 2019-05-31 | Kaye I Foster-Cheek | Director | Buy | 1,400.00 | 3,600.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119033618/0001209191-19-033618-index.htm | ||
| 2018-09-11 | JOHN MARAGANORE | Director | Sell | 2,400.00 | 73.82 | 177,168.00 | 36,209.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118050824/0001209191-18-050824-index.htm |
| 2020-02-05 | Christopher Bowden | Chief Medical Officer | Buy | 35,447.00 | 35.16 | 1,246,316.52 | 37,097.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000005/0001439222-20-000005-index.htm |
| 2019-05-31 | JOHN MARAGANORE | Director | Buy | 1,400.00 | 37,609.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119033625/0001209191-19-033625-index.htm | ||
| 2020-02-16 | Carman Alenson | Principal Accounting Officer | Buy | 2,800.00 | 3,774.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000019/0001439222-20-000019-index.htm | ||
| 2019-02-21 | Carman Alenson | Principal Accounting Officer | Buy | 3,300.00 | 3,812.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119012942/0001209191-19-012942-index.htm | ||
| 2020-05-29 | David Scadden | Director | Buy | 1,878.00 | 3,849.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000054/0001439222-20-000054-index.htm | ||
| 2018-09-11 | JOHN MARAGANORE | Director | Sell | 11,155.00 | 72.52 | 808,960.60 | 38,609.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118050824/0001209191-18-050824-index.htm |
| 2019-11-13 | JACQUALYN A FOUSE | Chief Executive Officer | Buy | 40,322.00 | 31.00 | 1,249,982.00 | 41,722.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922219000025/0001439222-19-000025-index.htm |
| 2020-02-16 | Christopher Bowden | Chief Medical Officer | Buy | 2,750.00 | 4,400.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000018/0001439222-20-000018-index.htm | ||
| 2018-10-05 | Scott Biller | Chief Scientific Officer | Sell | 21.00 | 71.77 | 1,507.17 | 50,932.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118054513/0001209191-18-054513-index.htm |
| 2018-11-05 | Scott Biller | Chief Scientific Officer | Sell | 100.00 | 71.42 | 7,142.00 | 50,932.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118057556/0001209191-18-057556-index.htm |
| 2018-10-05 | Scott Biller | Chief Scientific Officer | Sell | 1,100.00 | 71.05 | 78,155.00 | 50,953.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118054513/0001209191-18-054513-index.htm |
| 2018-11-05 | Scott Biller | Chief Scientific Officer | Sell | 700.00 | 70.23 | 49,161.00 | 51,032.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118057556/0001209191-18-057556-index.htm |
| 2018-11-05 | Scott Biller | Chief Scientific Officer | Sell | 2,200.00 | 69.44 | 152,768.00 | 51,732.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118057556/0001209191-18-057556-index.htm |
| 2018-10-05 | Scott Biller | Chief Scientific Officer | Sell | 979.00 | 69.47 | 68,011.13 | 52,053.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118054513/0001209191-18-054513-index.htm |
| 2018-10-05 | Scott Biller | Chief Scientific Officer | Sell | 900.00 | 68.56 | 61,704.00 | 53,032.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118054513/0001209191-18-054513-index.htm |
| 2018-10-05 | Scott Biller | Chief Scientific Officer | Buy | 3,000.00 | 9.05 | 27,150.00 | 53,932.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118054513/0001209191-18-054513-index.htm |
| 2018-11-05 | Scott Biller | Chief Scientific Officer | Buy | 3,000.00 | 9.05 | 27,150.00 | 53,932.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118057556/0001209191-18-057556-index.htm |
| 2020-04-13 | JACQUALYN A FOUSE | Chief Executive Officer | Buy | 12,379.00 | 54,101.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000030/0001439222-20-000030-index.htm | ||
| 2020-05-29 | Kaye I Foster-Cheek | Director | Buy | 1,878.00 | 5,478.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000052/0001439222-20-000052-index.htm | ||
| 2020-04-13 | Bruce Car | Chief Scientific Officer | Buy | 6,874.00 | 6,874.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000029/0001439222-20-000029-index.htm | ||
| 2020-02-22 | Christopher Bowden | Chief Medical Officer | Buy | 3,333.00 | 6,914.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000023/0001439222-20-000023-index.htm | ||
| 2019-01-20 | Christopher Bowden | Chief Medical Officer | Buy | 6,265.00 | 7,189.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119004950/0001209191-19-004950-index.htm | ||
| 2019-03-15 | Christopher Bowden | Chief Medical Officer | Sell | 1,300.00 | 64.64 | 84,032.00 | 7,238.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119020288/0001209191-19-020288-index.htm |
| 2019-04-01 | Christopher Bowden | Chief Medical Officer | Sell | 100.00 | 68.72 | 6,872.00 | 7,238.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119023072/0001209191-19-023072-index.htm |
| 2018-09-05 | David P Schenkein | Chief Executive Officer | Buy | 72,619.00 | 2.34 | 169,928.46 | 72,619.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118050064/0001209191-18-050064-index.htm |
| 2019-04-01 | Christopher Bowden | Chief Medical Officer | Sell | 1,500.00 | 68.09 | 102,135.00 | 7,338.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119023072/0001209191-19-023072-index.htm |
| 2018-09-05 | David P Schenkein | Chief Executive Officer | Buy | 2,500.00 | 31.64 | 79,100.00 | 75,119.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118050064/0001209191-18-050064-index.htm |
| 2019-02-16 | Carman Alenson | Principal Accounting Officer | Buy | 790.00 | 790.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119011483/0001209191-19-011483-index.htm | ||
| 2019-02-16 | Christopher Bowden | Chief Medical Officer | Buy | 2,750.00 | 8,013.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119011489/0001209191-19-011489-index.htm | ||
| 2020-05-20 | Christopher Bowden | Chief Medical Officer | Sell | 3,583.00 | 50.01 | 179,200.16 | 8,306.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000041/0001439222-20-000041-index.htm |
| 2018-09-10 | David P Schenkein | Chief Executive Officer | Buy | 8,730.00 | 31.64 | 276,217.20 | 83,849.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919118050631/0001209191-18-050631-index.htm |
| 2020-04-13 | Jonathan Biller | Chief Legal Officer | Buy | 8,523.00 | 8,523.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000032/0001439222-20-000032-index.htm | ||
| 2019-03-15 | Christopher Bowden | Chief Medical Officer | Sell | 8,700.00 | 64.09 | 557,583.00 | 8,538.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119020288/0001209191-19-020288-index.htm |
| 2020-02-22 | Carman Alenson | Principal Accounting Officer | Buy | 691.00 | 875.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000021/0001439222-20-000021-index.htm | ||
| 2020-02-13 | Christopher Bowden | Chief Medical Officer | Buy | 7,100.00 | 35.16 | 249,636.00 | 8,750.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000008/0001439222-20-000008-index.htm |
| 2019-04-01 | Christopher Bowden | Chief Medical Officer | Sell | 2,546.00 | 66.85 | 170,200.10 | 8,838.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119023072/0001209191-19-023072-index.htm |
| 2019-02-16 | David P Schenkein | Director | Buy | 8,125.00 | 91,974.00 | https://www.sec.gov/Archives/edgar/data/1439222/000120919119011498/0001209191-19-011498-index.htm | ||
| 2020-02-16 | Carman Alenson | Principal Accounting Officer | Buy | 790.00 | 974.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922220000019/0001439222-20-000019-index.htm | ||
| 2019-11-13 | David P Schenkein | Director | Buy | 8,064.00 | 31.00 | 249,984.00 | 97,567.00 | https://www.sec.gov/Archives/edgar/data/1439222/000143922219000023/0001439222-19-000023-index.htm |